亿腾嘉和(06998)：EDP167 II期临床试验完成首例受试者给药

Core Viewpoint - Eton Pharma (06998) announced the successful completion of the first dosing of its small nucleic acid innovative drug EDP167 in a Phase II clinical trial targeting adult patients with homozygous familial hypercholesterolemia (HoFH) [1] Group 1: Clinical Trial Details - The Phase II clinical trial for EDP167 is a multicenter, dose-exploration, open-label study [1] - The trial aims to evaluate the efficacy and safety of EDP167 in HoFH patients [1] - The primary endpoint is the change in low-density lipoprotein cholesterol (LDL-C) levels from baseline after 24 weeks of the first dosing [1] Group 2: Timeline - The evaluation of the primary endpoint is expected to be completed by the fourth quarter of 2026 [1]